Aryl-Aniline Compounds for Treatment of Skin Cancers
ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Summary
The European Patent Office published patent application EP3883553A1 for NFlection Therapeutics covering aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers. Co-applicants include H. Lee Moffitt Cancer Center & Research Institute. The patent was published March 25, 2026, designating 35 European contracting states.
What changed
EPO published patent EP3883553A1 granting NFlection Therapeutics and H. Lee Moffitt Cancer Center exclusive rights to aryl-aniline and heteroaryl-aniline compounds for therapeutic use in skin cancer treatment. The patent application claims compounds falling under multiple IPC classifications including A61K 31/136, A61K 31/192, and A61P 35/00. Designated contracting states span 35 European jurisdictions including all EU member states plus Switzerland, Norway, Turkey, and others.
This is an intellectual property notification rather than a regulatory compliance requirement. Pharmaceutical companies developing competing aryl-aniline or heteroaryl-aniline compounds for skin cancer indications should review the patent claims for potential licensing needs or freedom-to-operate analysis. No immediate compliance action is required.
Source document (simplified)
ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS
Publication EP3883553A1 Kind: A1 Mar 25, 2026
Applicants
NFlection Therapeutics, Inc., H. Lee Moffitt Cancer Center & Research Institute
Inventors
TSAI, Kenneth, Y., KINCAID, John, SARIN, Kavita, Yang
IPC Classifications
A61K 31/136 20060101AFI20220923BHEP A61K 31/192 20060101ALI20220923BHEP A61P 35/00 20060101ALI20220923BHEP A61K 31/277 20060101ALI20220923BHEP A61K 31/337 20060101ALI20220923BHEP A61K 31/381 20060101ALI20220923BHEP A61K 31/397 20060101ALI20220923BHEP A61K 31/40 20060101ALI20220923BHEP A61K 31/42 20060101ALI20220923BHEP A61K 31/4365 20060101ALI20220923BHEP A61K 31/437 20060101ALI20220923BHEP A61K 31/4375 20060101ALI20220923BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.